GeneDx Holdings Corp. Class A (WGS)

The past six months have seen significant volatility and negative impacts on GeneDx Holdings Corp.'s stock price. The company reported its first-quarter 2026 financial results, which significantly missed analyst expectations. Following the Q1 2026 results, GeneDx lowered its full-year 2026 revenue guidance by approximately $65 million. The stock price plummeted significantly after the Q1 2026 results were announced. Several law firms have announced investigations into GeneDx Holdings Corp. concerning potential violations of federal securities laws. The company took a $31.3 million non-cash impairment charge related to the goodwill and intangible assets of its Fabric Genomics reporting unit. Over the past 52 weeks, the stock has traded between a low of $32.21 and a high of $170.87.

An analysis of GeneDx Holdings Corp.'s seasonal charts suggests a historical "Buy Date of December 10 and a Sell Date of March 1," which has shown positive returns compared to the S&P 500 over the past five years. Despite recent financial setbacks, the company reported strong demand for its core services, with exome and genome testing volumes growing 34% year-over-year in Q1 2026.

GeneDx Holdings Corp. is a genomics and health intelligence company focused on translating complex genomic data into clinical answers, operating in the Healthcare sector, specifically the Diagnostics & Research industry. The company specializes in pediatric and rare disease diagnostics, with a strong emphasis on whole exome and genome sequencing. Major products and services include exome sequencing tests, genome sequencing tests, targeted variant testing, AI-powered genomic interpretation through Fabric Genomics, Inc., and data and information services.

GeneDx Holdings Corp. is headquartered in Stamford, Connecticut, United States. Its subsidiary, Fabric Genomics, Inc., is pivoting to focus on international opportunities for its interpretation-as-a-service offerings.

GeneDx Holdings Corp.'s brand reputation in the past year has been significantly impacted by recent negative financial news and subsequent legal actions. The widening net loss in Q1 2026, the substantial reduction in full-year revenue guidance, and the shift from projected profitability to an adjusted net loss have severely impacted investor confidence. The dramatic drop in stock price following the Q1 2026 earnings report has generated negative headlines and investor concern. The initiation of investigations by law firms into potential securities law violations further tarnishes the company's reputation. The $31.3 million write-down related to Fabric Genomics' goodwill and intangible assets indicates challenges in integrating acquired assets and achieving expected synergies.

GeneDx Holdings Corp. has a diverse ownership structure comprising institutional, retail, and individual investors. Approximately 32.59% to 45.22% of the company's stock is owned by institutional investors. Insiders own approximately 38.70% of the company's stock, with Eli Casdin identified as owning the most shares among insiders. Public companies and individual investors collectively own between 12.63% and 16.09% of the stock.